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Brief Communication
DESIGNING A MODEL OF DRUG
QUALITY ASSURANCE FOR IRAN
Elhami Gh. H1, Maleki MR2, Tabibi SJ3
ABSTRACT
Objective: To take up the project for designing a Drug Quality Assurance Model (GMP) for Iran.
Methodology: It is a descriptive and comparative study. GMP models from USA, EU, Australia and
Iran, and WHO, ICH and PIC/S were selected for the comparative study. Internet sites and
scientific journals were used for data collection. The comparative study determined the primary
proposed model. Then, based on Delphi technique, the primary model was evaluated by experts
and eventually the final model was designed, for application in Iran.
Results: The comparative study and feedbacks of experts determined the final proposed model
for pharmaceutical quality assurance (GMP) for Iran, which consisted of two parts. The first part
included thirteen chapters consisting sixty-two major titles. The second part consisted of
sixteen annexes.
Conclusion: Establishment of standards of the final model of GMP in the drug industry could lead
to the improvement of quality of national manufactured drugs, hence, promoting the population
health levels.
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INTRODUCTION
Drug Industry is currently the second larg-
est global industrial sector by market value.1
Often 20–50% of the recurrent government
health budget in developing countries is used
to procure drugs.2 In several developing coun-
tries, there is a great concern that the preva-
lence of low quality drugs is high.3 In addition,
the manufacturing of substandard medicines
remains a global concern.4 In the drug indus-
try, quality more accurately reflects adherence
to the rules as Good Manufacturing Practice
(GMP).5 GMPs are a set of manufacturing pro-
tocols designed to ensure that every batch of a
pharmaceutical product meets the very high
quality standards required for a drug.6 The
drugs must be manufactured in accordance
with GMP, the internationally accepted stan-
dard for the production of medicinal products.7
In an increasing number of countries, manu-
facturers are required to follow GMP guide-
lines.8 Therefore, the authors decided to make
a comparative study of drug quality assurance
systems of USA, EU, Australia and also WHO,
ICH and PIC/S  to design a model for Iran.
METHODOLOGY
This is a descriptive, cross sectional and
comparative study carried out in two phases.
The first phase was study of selected GMP
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models. The criteria such as history of applied
GMP model, to be leader and initiative for other
countries and degree of institutionalization of
drug quality assurance in the health system
was adopted for selecting the country. Accord-
ing to mentioned criteria, USA, EU and Aus-
tralia were selected. Indeed, in order to expand
the field of study and use of international
experiences, it was decided to study the GMP
models of WHO, ICH and PIC/S. After selec-
tion and review of models, basic principles of
GMP models were determined. These models
were compared on two basis. (I) first was about
the structures of models including number of
parts, chapters, annexes, major titles and
words of models (structural base) and (II) sec-
ond was about the illustrations of requirements
(contextual base). Table-I shows the compari-
son between six selected models based on their
structures. Comparative study of contexts of
models was carried out in two stages. In the
first stage, the chapters of models and in the
second stage the annexes were studied.
Table-II shows comparison of selected models.
At the end of comparative study, a model of
GMP for Iran was formed which had 13 chap-
ters and 18 annexes.
In the second phase, by using Delphi tech-
nique, opinion was sought from professionals
for the suggested model. In the first step, twelve
pharmaceutical companies were selected and
from each company a manager (from quality
assurance unit, production, etc.) was chosen
for opinion about the suggestive model. The
selected companies were followings:
Darupakhsh, Elhavi, Loghman, Caspian
Tamin, Faravardehaye Daruee Iran, Kimidaru,
Iran Hormon, Zahravi, Pars Minoo, Exir,
Sobhan Daru and Sina Daru. In the second step
Table-I: Comparison of six selected GMP models according to their structures including
number of parts, chapters, annexes, major titles and words.
GMP models Parts Chapters Annexes Major Titles Words(without annexes)
USA 2 11 0 60 13914
EU 2 9 19 43 13492
Australia 1 17 0 42 16895
WHO 2 9 17 43 13492
ICH 1 19 0 86 18177
PIC/S 2 9 18 43 13492
of Delphi technique, pharmaceutical experts
and inspectors of ministry were selected for
completing the questionnaires. In two steps,
hundred percent of questionnaires were com-
pleted and returned. After primary analysis
with SPSS software, the acceptance criterion
of 75% was determined. The chapters and an-
nexes that had acceptance rate below 75%
were deleted. All suggested chapters were
accepted, but two suggested annexes and three
major titles were rejected. Table-III shows the
final suggestive model of GMP for Iran.
Historical background of selected Models:
USA: In 1906 the original Food and Drugs Act
was passed by Congress.9 In 1938 the Federal
Food, Drug, and Cosmetic Act of 193814 and
in 1962 the Kefauver-Harris Drug Amend-
ments are passed.10,11 The principles of GMP of
USA (cGMP) are in “21 Code of Federal Regu-
lations Parts 210 and 211”.12
EU: The first edition of the European GMP was
published in 1989. In 2005 re-structuring of
GMP guide was carried out. The current guide
includes 9 chapters and 18 annexes.13
Australia: The Australian Code of Good Manu-
facturing Practice was first published in 1969.
It was revised four times over the following
years, before the latest version was published
in 2002.14-16
WHO: The first WHO draft text on GMP was
prepared in 1967. Later, the text was revised
four times. The latest version of the GMP was
published in 2003 and is more similar to EU
model.17
ICH: ICH was created in 1990. The main
focus of the ICH process is the preparation of
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Table-II: Contextual comparison of selected six GMP models based on main concepts.
Main USA EU WHO Australia ICH PIC/S
Concepts
1. Quality Subpart A: 1. Quality 1.Quality 1.Quality 2.Quality 1.Quality
Management Management assurance Management Management Management
General 2. Self 2.Good 2. Self 2. Self
Provisions  Inspection manufacturing Inspection Inspection
practices for
pharmaceutical products (GMP)
8.Self-inspection and quality audits
2. Personnel Subpart B: 2.Personnel 9.Personnel 2.Personnel 3.Personnel 2. Personnel
Personnel 10.Training
11.Personal hygiene
3. Premises and Subpart C: 3.Premises and 3.Sanitation and 3.Premises and 4.Buildings 3.Premises and
facilities Buildings and Equipments hygiene Equipments  facilities Equipments
facilities 12.Premises
4. Equipment Subpart J: 3.Premises and 13.Equipment 3.Premises and 5. Process 3.Premises and
Records and Equipments Equipments Equipments Equipments
reports
5. Documentation Subpart E:        4. Documentation 4.Qualification 4. Documenta- 6. Documen- 4.Documen
and records Control of and records  and validation tion and tation tation and
components records and record records
and drug product 15.Documentation
containers and closures
6. Materials Subpart F:       ---- 14.Materials       ---- 7. Materials      ----
Management Production and Management
process controls
7. Production and Subpart F: 5. Production 16.Good 5. Production 8. Production 5. Production
In process control Production and practices and In process
process controls in production control
8. Packaging and Subpart G:       ---       ---       --- 9. Packaging       ----
labeling Packaging and Identification
labeling control labelingof APIs
and Intermediates
9. Storage and Subpart H:       ---       ---       --- 10. Storage       ---
distribution Holding and and distribution
distribution
10. Laboratory Subpart I: 6. Quality 17.Good 6. Quality 11. Laboratory  6. Quality
Controls Laboratory Control practices Control  Controls       Control
Controls in quality
control
11. Rejection and Subpart K:       ---       ---       --- 14. Rejection and       ---
Re-use of Returned and Re-use of
materials salvaged drug products materials
12. Complaints       --- 8.Complaints 5.Complaints 8.Complaints 15.Complaints   8.Complaints
and recalls and Product 6.Product and Product and recalls     and Product
recalls recalls recalls     recalls
13. Contract       --- 7. Contract 7.Contract 7. Contract 16. Contract 7. Contract
manufacture and manufacture production manufacture manufacture manufacture
analysis and analysis and analysis and analysis (Including and analysis
laboratories)
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Table-III: Schematic view of final suggested
quality assurance (GMP) model for Iran.
GMP
Chapters Annexes
1. Quality 1. Manufacture of
management sterile medicinal products
2. Personnel 2. Manufacture of biological
medicinal product for human use
3. Premises and 3. Manufacture of
Facilities Radiopharmaceuticals
4.Equipment 4. Manufacture of Veterinary
medicinal products other than
immunological veterinary
medicinal products
5. Documentation 5. Manufacture of & Records
immunological veterinary
6. Materials 6. Manfacture of Medicinal
Management Gases
7. Production and 7. Manufacture of herbal
in process control medicinal products
8. Packaging and 8. Sampling of starting and
labeling packaging materials
9. Stroge and 9. Manufacture of liquids,
distribution creams and ointments
10. Laboratory 10.Manufacture of pressurised
control metered dose aerosol
preparations for inhalation
11. Rejection and 11. Computerized system
re-use of materials
12. Complaints and 12. Manfacture of
recalls investigational medicinal
13. Contract 13. Manufacture of Medicinal
manufacture and products derived from human
analysis blood or plasma
14. Qualification and
validation
15. Certification by a qualified
person and batch release
16. Reference and retention
samples
Inspection Co-operation Scheme (PIC Scheme)
operating together in parallel. PIC/S became
operational in November 1995.20 The last
version of its GMP is published in 2006.20
Iran: The first medical law in Iran was
approved in 1955 as “Medical, Drug, Food and
Drink Regulations”. In 1957 and later in 1987,
the regulations were revised and some changes
were made. In 1988, “Regulations of Drug
Manufacture and Importation” was
approved.21 In 2004, a draft under the title of
Good Manufacturing Practice (GMP) of Phar-
maceutical Products for Human and Veterinary
Use, was published by the Drug Regulatory
Authority of Health Ministry.22 In the preface
of draft it is stated that the book has been  pub-
lished as a draft to receive readers suggestions
and after completion of draft, the first edition
of it will be published. It should be noted that
after passing three years of the draft publish-
ing, there is no declared official standard
reference (the first edition of GMP) to
pharmaceutical companies in Iran.
DISCUSSION
A considerable part of health budget in
developing countries is used to procure drugs.1
Surely, in order to preventing of wasting of
such important sources in health system, there
should be a great attention to quality of medi-
cines.2 Only about 20% of countries have well
developed and operational medicines regula-
tion.4 It has shown that the poor quality medi-
cines could result in treatment failure and re-
sistance.23-25 O’Brien and coworkers26 in a re-
ported outbreak of 88 paediatric deaths caused
by diethylene glycol poisoning and
Langerman6 in a report of 5 deaths from China
in 2006 caused by the drug Armillarisin A,
stated that the similar disaster will continue to
occur until countries establish regulations that
ensure the quality and safety of pharmaceuti-
cal products.Ovretveit27 believes that one of the
four ways to improve quality is to use meth-
ods designed specifically to improve quality.
GMP provides clear defined standards for
employees.28 Implementation of GMP in a
harmonized guidelines that can be adopted in
the three ICH regions.18 In 2000, ICH published
a relatively complete GMP guide consisting of
ICH regions opinions.18,19
PIC/S: PIC/S is the abbreviation and logo used
to describe both the Pharmaceutical Inspection
Convention (PIC) and the Pharmaceutical
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pharmaceutical company can enhance the
competitive factors of company worldwide so
it is a basic requirement 7,29,30 has an important
role in organizational success and excel-
lence31,32 and is one of the basic principles of
quality assurance in developed countries.33,34
Several countries have attempted to establish
the GMP in their health systems.8,19 In drug
industry, GMP implementation has been mani-
fested its important role in various productions
as OTC35, cosmetics,36 dietary supplements and
ingredients,37 exipients,38 biopharmaceu-
ticals,39 herbal medicines,40,41 vaccines,42
nanomedicines,43 gene therapy44 and tradi-
tional medicines.45 Based on the needs to im-
prove and maintain the quality of medicines
in Iran, GMP standards need to be imple-
mented. Our suggested model of GMP is an
attempt in achieving this objective.
CONCLUSION
Establishment of standards of the final model
of GMP in the drug industry of Iran can lead
to the improvement of quality of local manu-
factured drugs and promoting the population
health levels by following mechanisms46: com-
municating the culture of quality assurance in
drug industry and presenting the practical
strategies for improving the quality of medi-
cines; availability of high quality medicines to
public and prevention of potential risks caused
by consumption of low quality medicines; fos-
tering the movement toward “The Fourth Cul-
tural, Economical and Social Development
Plan (2005-2009) of Islamic Republic of Iran”,
specially articles 87, 88 part A and article 94
of chapter 7 (Health promotion and Life
improvement).47
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